ATE449174T1 - Neue peptide - Google Patents

Neue peptide

Info

Publication number
ATE449174T1
ATE449174T1 AT07006224T AT07006224T ATE449174T1 AT E449174 T1 ATE449174 T1 AT E449174T1 AT 07006224 T AT07006224 T AT 07006224T AT 07006224 T AT07006224 T AT 07006224T AT E449174 T1 ATE449174 T1 AT E449174T1
Authority
AT
Austria
Prior art keywords
amino acid
new peptides
compound
activity
replaced
Prior art date
Application number
AT07006224T
Other languages
English (en)
Inventor
Kenji Kangawa
Masayasu Kojima
Hiroshi Hosoda
Hisayuki Matsuo
Yoshiharu Minamitake
Original Assignee
Kenji Kangawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenji Kangawa filed Critical Kenji Kangawa
Application granted granted Critical
Publication of ATE449174T1 publication Critical patent/ATE449174T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT07006224T 1999-07-23 2000-07-24 Neue peptide ATE449174T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21000299 1999-07-23
JP33884199 1999-11-29
JP2000126623 2000-04-26

Publications (1)

Publication Number Publication Date
ATE449174T1 true ATE449174T1 (de) 2009-12-15

Family

ID=27329078

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07006224T ATE449174T1 (de) 1999-07-23 2000-07-24 Neue peptide
AT00946453T ATE366813T1 (de) 1999-07-23 2000-07-24 Neue peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00946453T ATE366813T1 (de) 1999-07-23 2000-07-24 Neue peptide

Country Status (16)

Country Link
US (5) US7385026B1 (de)
EP (3) EP1795598B1 (de)
JP (2) JP3471780B2 (de)
KR (1) KR100827973B1 (de)
CN (2) CN100506844C (de)
AT (2) ATE449174T1 (de)
AU (2) AU784035B2 (de)
BR (2) BR0012688A (de)
CA (2) CA2380058C (de)
CY (2) CY1107724T1 (de)
DE (2) DE60035502T2 (de)
DK (2) DK1795598T3 (de)
ES (3) ES2401939T3 (de)
IL (2) IL147652A0 (de)
PT (2) PT1795598E (de)
WO (1) WO2001007475A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449174T1 (de) 1999-07-23 2009-12-15 Kenji Kangawa Neue peptide
ATE435871T1 (de) * 1999-11-22 2009-07-15 Zymogenetics Inc Methode zur bildung einen peptid-rezeptor komplex mit zsig33 polypeptiden.
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
DE60135985D1 (de) 2000-05-12 2008-11-13 Kaneka Corp Verfahren zur reinigung von vinylpolymer
JP2004514651A (ja) * 2000-05-30 2004-05-20 メルク　エンド　カムパニー　インコーポレーテッド グレリン類似体
AU2001283938A1 (en) * 2000-07-24 2002-02-05 Ardana Bioscience Limited Ghrelin antagonists
WO2003084983A1 (fr) * 2002-04-11 2003-10-16 Daiichi Suntory Pharma Co., Ltd. Procede de production d'un peptide modifie
IL162796A0 (en) 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
PT1578778E (pt) * 2002-07-23 2011-03-07 Ipsen Pharma Análogos de grelina
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
EP1407779A1 (de) 2002-10-10 2004-04-14 Gastrotech A/S Verwendung von Ghrelin zur Behandlung von vermindertem Körpergewicht und Körperfett in Individuen mit Gastrektomie
US10653637B2 (en) 2003-04-30 2020-05-19 Kenji Kangawa Preventives or remedies for hepatopathy
EP1633397A2 (de) * 2003-06-04 2006-03-15 Eli Lilly And Company Anti-ghrelin fab antikörper
EP1670827A2 (de) * 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin-antikörper
CN1321131C (zh) * 2003-12-26 2007-06-13 李宁 猪Ghrelin衍生物及其编码基因与应用
JP2007518762A (ja) * 2004-01-20 2007-07-12 サイトス バイオテクノロジー アーゲー グレリン−担体結合体
US7026175B2 (en) 2004-03-29 2006-04-11 Applied Materials, Inc. High throughput measurement of via defects in interconnects
EP1742655A2 (de) * 2004-04-07 2007-01-17 Gastrotech Pharma A/S Verwendung von ghrelin zur behandlung von hyperthyreose
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
US20080269116A1 (en) * 2004-05-11 2008-10-30 Taub Dennis D Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
CA2569235A1 (en) * 2004-07-14 2006-02-23 Eli Lilly And Company Anti-ghrelin antibodies
WO2006045319A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
JP2008521840A (ja) * 2004-11-30 2008-06-26 ガストロテック・ファルマ・アクティーゼルスカブ 成長ホルモン分泌促進物質レセプター１ａリガンド
EP1856154A1 (de) 2005-02-23 2007-11-21 Eli Lilly And Company Humanisierte antighrelin-antikörper
EP1862173B1 (de) * 2005-02-23 2014-12-17 Kyoto University Promotor der regeneration einer pankreatischen zelle und promotor der insulinproduktion in einer pankreatischen zelle
PT1937262T (pt) 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
KR20080075530A (ko) * 2005-11-21 2008-08-18 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 그렐린, 그 유도체 또는 ＧＨＳ-Ｒ1ａ에 작용하는 물질을유효 성분으로 포함하는 피부 수복 촉진 치료제
RU2008125167A (ru) * 2005-11-21 2009-12-27 Юниверсити Оф Миязаки (Jp) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные
EP2012809B1 (de) * 2006-03-10 2013-05-22 Ipsen Pharma Verwendung eines ghrelin-agonisten zur erhöhung der katabolischen wirkung einer glukokortikoidbehandlung
CA2645844C (en) 2006-03-13 2016-04-26 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
AU2007281131B2 (en) * 2006-08-01 2012-11-29 The Scripps Research Institute Vaccines and methods for controlling adiposity
CN101516399A (zh) * 2006-08-11 2009-08-26 国立大学法人宫崎大学 以去酰基化的生长素释放肽及其衍生物作为有效成分的脊髓神经修复促进治疗剂
WO2008018600A1 (fr) 2006-08-11 2008-02-14 University Of Miyazaki AGENT THÉRAPEUTIQUE PERMETTANT D'ACCÉLÉRER LA RÉPARATION DES NERFS RACHIDIENS COMPRENANT EN TANT QUE MATIÈRE ACTIVE DE LA GHRÉLINE, UN DÉRIVÉ DE CELLE-CI OU UNE SUBSTANCE CAPABLE D'AGIR SUR LE GHS-R1a
RU2459831C2 (ru) * 2006-09-27 2012-08-27 Ипсен Фарма С.А.С. Аналоги грелина с замещением на n-конце
JP5524049B2 (ja) 2008-05-23 2014-06-18 第一三共株式会社 目的ペプチドの血漿中半減期延長作用を有するペプチド
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2524697B1 (de) 2010-01-15 2016-09-21 University of Miyazaki Ghrelin zur förderung der erholung von tieren in medizinischer behandlung
US9315546B2 (en) * 2010-06-16 2016-04-19 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
JP5999712B2 (ja) 2011-03-03 2016-09-28 国立大学法人 宮崎大学 高体温治療剤
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
WO2013130684A1 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
KR102238317B1 (ko) 2012-05-17 2021-04-12 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
WO2014065341A1 (ja) 2012-10-24 2014-05-01 第一三共株式会社 筋萎縮性側索硬化症治療剤
WO2014119753A1 (ja) * 2013-01-31 2014-08-07 学校法人 東京薬科大学 マイオスタチン阻害ペプチド
JP6295247B2 (ja) * 2013-03-25 2018-03-14 ゼリア新薬工業株式会社 食後期の胃運動亢進剤
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
AU2020382621A1 (en) 2019-11-13 2022-06-02 Amunix Pharmaceuticals, Inc. Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
EP0635025B1 (de) * 1992-04-07 2002-11-06 The Scripps Research Institute Verfahren zur herstellung modifizierten proteine
IL118473A0 (en) 1995-06-02 1996-09-12 Suntory Ltd Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof
JP3982866B2 (ja) 1996-03-04 2007-09-26 アスビオファーマ株式会社 分泌型Ｋｅｘ２誘導体の製造方法
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
WO1998042840A1 (en) 1997-03-24 1998-10-01 Zymogenetics, Inc. Motilin homologs
IL139686A0 (en) * 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
ATE449174T1 (de) * 1999-07-23 2009-12-15 Kenji Kangawa Neue peptide

Also Published As

Publication number Publication date
EP2119785B1 (de) 2013-03-13
US9573986B2 (en) 2017-02-21
BRPI0012688B8 (pt) 2021-05-25
DE60035502D1 (de) 2007-08-23
AU2006201580B2 (en) 2009-01-08
IL147652A0 (en) 2002-08-14
DK1197496T3 (da) 2007-10-22
IL147652A (en) 2010-04-29
US9938332B2 (en) 2018-04-10
AU2006201580A1 (en) 2006-05-18
ES2335235T3 (es) 2010-03-23
EP2119785A1 (de) 2009-11-18
KR100827973B1 (ko) 2008-05-21
CY1109714T1 (el) 2014-08-13
ES2288151T3 (es) 2008-01-01
ES2401939T3 (es) 2013-04-25
KR20020026543A (ko) 2002-04-10
EP1795598B1 (de) 2009-11-18
US7385026B1 (en) 2008-06-10
US20090170763A1 (en) 2009-07-02
ATE366813T1 (de) 2007-08-15
EP1197496B1 (de) 2007-07-11
CN1362968A (zh) 2002-08-07
US8524871B2 (en) 2013-09-03
CA2380058C (en) 2011-08-09
CN101693736A (zh) 2010-04-14
CA2380058A1 (en) 2001-02-01
EP1197496A1 (de) 2002-04-17
US8227570B2 (en) 2012-07-24
BRPI0012688B1 (pt) 2018-06-05
BR0012688A (pt) 2002-04-16
CA2696819C (en) 2015-07-07
CN100506844C (zh) 2009-07-01
CN101693736B (zh) 2020-09-11
DK1795598T3 (da) 2010-02-01
CA2696819A1 (en) 2001-02-01
US20110184153A1 (en) 2011-07-28
AU6023100A (en) 2001-02-13
US20100240866A1 (en) 2010-09-23
PT1197496E (pt) 2007-08-29
DE60043361D1 (de) 2009-12-31
US20130172251A1 (en) 2013-07-04
JP4227857B2 (ja) 2009-02-18
AU784035B2 (en) 2006-01-19
JP2004000251A (ja) 2004-01-08
EP1795598A1 (de) 2007-06-13
EP1197496B8 (de) 2007-10-03
CY1107724T1 (el) 2013-04-18
JP3471780B2 (ja) 2003-12-02
WO2001007475A1 (fr) 2001-02-01
PT1795598E (pt) 2010-01-05
DE60035502T2 (de) 2008-03-20
EP1197496A4 (de) 2002-11-20

Similar Documents

Publication Publication Date Title
ATE449174T1 (de) Neue peptide
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
ATE458054T1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
ATE497390T1 (de) Neue therapeutische verwendung von smr-1 peptide
DE69220861D1 (de) Zyklische Peptide und ihre Verwendung
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
EP0270214A3 (de) Vasopressinantagonisten
BR0214363A (pt) Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção
BR9712033A (pt) Composição farmacêutica para tratamento de doenças virais.
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
GB0207644D0 (en) Peptides and their use
EP1467207A4 (de) Screening-verfahren
EP1760087A4 (de) Neuer proteinkomplex und anwendungen davon
WO2003022300A1 (fr) Remedes prophylactiques et curatifs contre les maladies des os et des articulations
ATE46173T1 (de) Pharmakologisch aktive peptide.
TH18962A (th) สารผสมที่ทำให้ขนร่วงซึ่งประกอบด้วยสารประกอบซัลฟ์ไฮดริล
WO2003029290A1 (fr) Transporteur de medicament et son utilisation
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "
EP1308512A4 (de) Neuartige proteine und deren dna
DE69508496T2 (de) Endothelin-antagonisierendes Peptid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1795598

Country of ref document: EP